Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Biol Psychiatry. 2018 Dec 27;86(2):143–152. doi: 10.1016/j.biopsych.2018.12.014

Figure 4.

Figure 4.

The antidepressant-like effects of intra-mPFC VEGF infusion are blocked by co-infusion of BDNF nAb. (A) Experimental timeline for behavioral testing after intra-mPFC infusion of control IgG (200 ng/side), BDNF nAb (200 ng/side), IgG + VENF (5 ng/side), or BDNF nAb + VEGF. (B) Immobility time in the FST1 1 day after intra-mPFC infusion (interaction, F1,18 = 5.58, p = .00296, n = 5–6). (C) Immobility time in the FST2 2 days after intra-mPFC infusion (interaction, F1,18 = 21.4, p = .0002, n = 5–6). (D) LMA 3 days after intra-mPFC infusion (interaction, F1,18 = 1.24, p = .280; BDNF nAb, F1,18 = 2.09, p = .166; VEGF, F1,18 = 1.20, p = .288, n = 5–6). (E) Time spent sniffing female urine in the FUST 4 days after intra-mPFC infusion (interaction, F1,18 = 7.36, p = .0142, n = 5–6). (F) Latency to feed in the NSF 5 days after intra-mPFC infusion (interaction, F1,18 = 4.61, p = .0456, n = 5–6). (G) HCF just after the NSF (interaction, F1,18 = .112, p = .741; BDNF nAb, F1,18 = .00702, p = .934; VEGF, F1,18 = 1.80, p = .197, n = 5–6). (H) Schematic representation of mPFC infusion sites. Data are expressed as means ± SEM. *p < .05, **p < .01, ***p < .001.